Free Trial

XBiotech Q2 2023 Earnings Report

XBiotech logo
$2.99 -0.13 (-4.17%)
As of 02/21/2025 04:00 PM Eastern

XBiotech EPS Results

Actual EPS
-$0.29
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

XBiotech Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

XBiotech Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

XBiotech Earnings Headlines

Market down? Do this now.
During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now, history is repeating itself. Here's the truth: Tariffs create uncertainty. Uncertainty drives investors to gold. And gold prices rise as a result. It's a cycle that's already beginning again—and it's your chance to profit. Why wait? Greed isn't always a bad thing—especially when it comes to protecting and growing your wealth. The smartest investors are already moving their money into gold, and you should too.
See More XBiotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like XBiotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on XBiotech and other key companies, straight to your email.

About XBiotech

XBiotech (NASDAQ:XBIT), a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

View XBiotech Profile

More Earnings Resources from MarketBeat